We are a biotechnology research corporation striving for the development of health solutions for people, with a special focus on maternal and fetal health, human reproduction, and women’s health.
MELISA integrates diverse areas of human life sciences including basic sciences, epidemiology, and medicine. Our institution’s core capabilities include: advanced research in proteomics, genomics and the development and manufacturing of medical products with diagnostic or therapeutic applications. In addition, MELISA Institute is interested in investigating biological and social determinants of health at the population level.
Our Institute has developed a research platform that enables us to get closer to deciphering the in vivo molecular dialogue between the embryo and its mother, in the period from fertilization to nesting in the uterus. The main feature of our research is our in vivo platform based on the collection of biological specimens from a preconception cohort. Through the integration of various analytical technologies we seek to reveal these signals and find biomarkers of this process.
During the current global health emergency provoked by the COVID-19 outbreak, MELISA rapidly adapted its research platform to collaborate in investigating clinical applications and possible solutions to this major public health crisis.
A randomized Clinical Trial to prevent Covid-19
MELISA Institute’s research aims for chemoprophylaxis against Covid-19 through the use of Previfenon®, preventing an effective incubation and enhancing systemic immunity.